Skip to main content

Advertisement

Table 4 Summary of studies showing the efficacy of anti-vascular endothelial growth factor therapy in inflammatory choroidal neovascularization (studies with sample size ≥ 5 eyes)

From: An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management

Author (year); country Design; sample size Disease Mean no of injections; agent Mean follow-up Efficacy outcomes
Roy et al. (2017); India [18] Retrospective; 30 eyes (28 patients) Idiopathic choroiditis, toxoplasmosis, panuveitis, VKH, serpiginous choroiditis 2.76; (bevacizumab, ranibizumab) 17.93 ± 14.28 months Improvement in visual acuity in 53.3%; stabilization in 26.6%
Korol et al. (2017); Ukraine [154] Prospective cohort; 15 eyes (14 patients) Toxoplasmosis 1.7 (aflibercept) 12 months Visual acuity improved from 0.36 to 0.64 (p = 0.0002)
Parodi et al. (2014); Italy [76] Prospective; 7 eyes (7 patients) Serpiginous choroiditis 1 injection in 12 months (bevacizumab) 12 months Visual acuity improvement in 52% and stabilization in 57%
Mansour et al. (2012); Lebanon [155] Retrospective; 8 eyes (8 patients) VKH, PIC, toxoplasmosis 1.375 (bevacizumab) 5 years Visual acuity improved (median gain of 3.8 lines)
Iannetti et al. (2013); Italy [156] Prospective study; 8 eyes (8 patients) Posterior uveitis 3.75 ± 1.38 (bevacizumab) 19.25 ± 6 months Visual acuity improved from 0.27 to 0.5 (p < 0.05)
Julian et al. (2011); France [157] Retrospective; 15 eyes (15 patients) Multifocal choroiditis with panuveitis, ampiginous choroiditis, and others 4.25 (in 12 eyes); 3 eyes received only 1 injection (bevacizumab) 17.6 months Visual acuity improved from 0.53 to 0.29
Cornish et al. (2011); UK [158] Retrospective; 9 eyes (9 patients) PIC 2.34 injections per year (bevacizumab and ranibizumab) 14.9 months Visual acuity gain was 0.36 LogMAR units
Kramer et al. (2010); Israel [159] Retrospective; 10 eyes (10 patients) Multifocal choroiditis, PIC, toxoplasmosis, POHS, serpiginous choroiditis, and panuveitis 2.7 ± 2 (bevacizumab) 13 ± 8 months Visual acuity improved from 0.87 ± 0.74 to 0.38 ± 0.63 (p = 0.005)
Lott et al. (2009); USA [160] Retrospective; 34 eyes (30 patients) Multifocal choroiditis, PIC, VKH, idiopathic panuveitis, sarcoidosis, serpiginous choroiditis, toxocariasis, POHS, CMV retinitis, and others 2 (bevacizumab) 7 months At 6 months, visual acuity improved in 17% and stabilized in 33%
Doctor et al. (2009); USA [161] Retrospective; 6 eyes (5 patients) Idiopathic panuveitis, birdshot chorioretinopathy, sympathetic ophthalmia, VKH, and multifocal choroiditis and panuveitis 2.7 (bevacizumab) 15.3 months Visual acuity improved in 60% of cases
Fine et al. (2009); USA [95] Retrospective; 6 eyes (5 patients) Multifocal choroiditis 2.3 (bevacizumab) 6 months 5/6 eyes improved to 20/30 acuity or better at 6 months
Schadlu et al. (2008); USA [87] Retrospective; 28 eyes (28 patients) POHS 1.8 (bevacizumab) 22.43 weeks Visual acuity improved from 0.65 to 0.43 LogMAR units
Adan et al. (2007); Spain [162] Retrospective; 9 eyes of 9 patients PIC, serpiginous choroiditis, multifocal choroiditis, POHS, and birdshot chorioretinopathy 7 eyes received 1 injection (bevacizumab) 7.1 months CNV resolved completely in 100% affected eyes
  1. CNV choroidal neovascularization, CMV cytomegalovirus, PIC punctate inner choroidopathy, POHS presumed ocular histoplasmosis syndrome, VKH Vogt-Koyanagi-Harada’s disease